Neoantigen: A Long March toward Cancer Immunotherapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27006495.
- Also identified by DOI 10.1158/1078-0432.CCR-15-3170 and PMC identifier 4891220.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Somatic mutations in cancer give rise to neoantigens. Technology revolutions in cancer genomics and immunology have made it possible to rapidly identify neoantigens for cancer vaccines. Leisegang and colleagues report that it is practical to rapidly identify neoantigens for adoptive T-cell therapy in a mouse tumor model. Clin Cancer Res; 22(11); 2602-4. ©2016 AACRSee related article by Leisegang et al., p. 2734.
Medical subject headings
- Neoplasms
- Point Mutation